BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

In June 2004, Immuno-Designed Molecules S.A. pulled its proposed E99 million ($119 million) IPO on Euronext in Paris when French investors proved uninterested. The cancer immunotherapy company concluded that the only way to gain access...
BioCentury | May 7, 2007
Finance

Global visibility

On the face of it, Europe seems to have all the pieces in place. Capital is available from public and private sources, there are clusters of world class science and technology, companies have been able...
BC Week In Review | Mar 19, 2007
Company News

Micromet, Tracon deal

MITI granted Tracon exclusive, worldwide rights to develop and commercialize D93 to treat cancer. In 2H07, Tracon plans to begin a Phase I trial of the recombinant humanized IgG1 MAb that inhibits angiogenesis, tumor cell...
BioCentury | Mar 19, 2007
Finance

Ebb & Flow

Two new companies, Tragara Pharmaceuticals and Epiphany Biosciences , landed large series A rounds last week. Each was formed around recently in-licensed compounds and hopes to get to a major value inflection point, Phase IIb results,...
BC Extra | Mar 17, 2007
Company News

Micromet, Tracon cancer deal

MITI granted Tracon (San Diego, Calif.) exclusive, worldwide rights to develop and commercialize D93 to treat cancer. MITI could receive upfront and milestone payments of more than $100 million, plus royalties. In 2H07, Tracon plans...
BC Week In Review | Jan 1, 2007
Company News

Receptor BioLogix management update

Receptor BioLogix Inc. , South San Francisco, Calif.   Business: Cancer   Hired: Janet Swearson as CFO, formerly CFO and VP of finance and operations at Threshold Pharmaceuticals Inc. ; Guy Gammon as CMO, formerly VP...
BC Week In Review | Oct 9, 2006
Company News

Curis, Micromet cancer, neurology, dermatology news

CRIS agreed to settle a lawsuit against MITI in a German court (Landgericht Muenchen), in which CRIS had been seeking repayment of the E2 million ($2.5 million) balance remaining on a note owed by MITI....
BioCentury | Oct 9, 2006
Finance

Ebb & Flow

Biotech had a good first week of the quarter, reflected by a 3.4% jump in the BioCentury 100 Index on the back of biotech-to-biotech M&A news and robust after-market support for companies issuing new paper....
BioCentury | Sep 25, 2006
Strategy

Midcap wake-up call

For years, it has been an open secret that many of Europe's family-owned mid-cap pharmas have been lost at sea, unable to adapt to the new world of innovative in-house R&D and aggressive in-licensing. Merck...
Items per page:
1 - 10 of 159
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

In June 2004, Immuno-Designed Molecules S.A. pulled its proposed E99 million ($119 million) IPO on Euronext in Paris when French investors proved uninterested. The cancer immunotherapy company concluded that the only way to gain access...
BioCentury | May 7, 2007
Finance

Global visibility

On the face of it, Europe seems to have all the pieces in place. Capital is available from public and private sources, there are clusters of world class science and technology, companies have been able...
BC Week In Review | Mar 19, 2007
Company News

Micromet, Tracon deal

MITI granted Tracon exclusive, worldwide rights to develop and commercialize D93 to treat cancer. In 2H07, Tracon plans to begin a Phase I trial of the recombinant humanized IgG1 MAb that inhibits angiogenesis, tumor cell...
BioCentury | Mar 19, 2007
Finance

Ebb & Flow

Two new companies, Tragara Pharmaceuticals and Epiphany Biosciences , landed large series A rounds last week. Each was formed around recently in-licensed compounds and hopes to get to a major value inflection point, Phase IIb results,...
BC Extra | Mar 17, 2007
Company News

Micromet, Tracon cancer deal

MITI granted Tracon (San Diego, Calif.) exclusive, worldwide rights to develop and commercialize D93 to treat cancer. MITI could receive upfront and milestone payments of more than $100 million, plus royalties. In 2H07, Tracon plans...
BC Week In Review | Jan 1, 2007
Company News

Receptor BioLogix management update

Receptor BioLogix Inc. , South San Francisco, Calif.   Business: Cancer   Hired: Janet Swearson as CFO, formerly CFO and VP of finance and operations at Threshold Pharmaceuticals Inc. ; Guy Gammon as CMO, formerly VP...
BC Week In Review | Oct 9, 2006
Company News

Curis, Micromet cancer, neurology, dermatology news

CRIS agreed to settle a lawsuit against MITI in a German court (Landgericht Muenchen), in which CRIS had been seeking repayment of the E2 million ($2.5 million) balance remaining on a note owed by MITI....
BioCentury | Oct 9, 2006
Finance

Ebb & Flow

Biotech had a good first week of the quarter, reflected by a 3.4% jump in the BioCentury 100 Index on the back of biotech-to-biotech M&A news and robust after-market support for companies issuing new paper....
BioCentury | Sep 25, 2006
Strategy

Midcap wake-up call

For years, it has been an open secret that many of Europe's family-owned mid-cap pharmas have been lost at sea, unable to adapt to the new world of innovative in-house R&D and aggressive in-licensing. Merck...
Items per page:
1 - 10 of 159